PsA Clinical Trial
— Metrix IIOfficial title:
Closing the Gap in Care in Seronegative Inflammatory Arthritis: From Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change
Verified date | April 2017 |
Source | Pope Research Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rheumatologists treating patients with seronegative arthritis will be randomized to treat their patients to a target or to treat their patients under their usual standard of care. All physicians will perform an initial chart audit. Following the initial chart audit, all physicians in the treat-to-target group will receive accredited educational training. Six months after the initial chart audit, all physicians will perform a repeat audit to see if patients are assessed more systematically and treated to a target of low disease state.
Status | Completed |
Enrollment | 40 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Canadian Rheumatologist Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
Canada | Dr. Vandana Ahluwalia | Brampton | Ontario |
Canada | Dr. Sanjay Dixit | Burlington | Ontario |
Canada | Dr Pauline Boulos | Hamilton | Ontario |
Canada | Dr. Nikhil Chopra | London | Ontario |
Canada | Credit Valley Rheumatology | Mississauga | Ontario |
Canada | Dr Angela Montgomery | Mississauga | Ontario |
Canada | The Medical Centre | Peterborough | Ontario |
Canada | Dr. Arthur Karasik | Toronto | Ontario |
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Pope Research Corporation | Abbott, Academic Medical Organization of Southwestern Ontario |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of Systematic Assessments | Physicians in the Education and Feedback arm are assessed via a needs assessment to identify the care gaps for their patients with inflammatory arthritis. After the education and feedback, they complete a second chart audit and their improvements in assessments is recorded. | November 2012 - November 2013 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05629494 -
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
|
Phase 4 | |
Recruiting |
NCT04081636 -
Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications
|
N/A | |
Terminated |
NCT02455466 -
Altered PSA Test Due to Possible Suspected Heterophilic Antibodies
|
N/A | |
Completed |
NCT02934620 -
Promoting CSD500 Use Among Women in Established Relationships
|
N/A | |
Recruiting |
NCT04240327 -
Marker Driven Selection of Patients for Prostate Biopsy and Management
|
||
Recruiting |
NCT04319783 -
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
|
Phase 2 | |
Recruiting |
NCT03428087 -
Prostate Impendance Test Project
|
N/A | |
Recruiting |
NCT04251546 -
Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV
|
||
Recruiting |
NCT03891732 -
MRI Prostate for Chinese Men Being Screened for Prostate Cancer
|
||
Recruiting |
NCT03784924 -
EDRN Prostate MRI Biomarker Study
|
||
Terminated |
NCT01681433 -
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
|
Phase 2 | |
Active, not recruiting |
NCT04782713 -
Smart Prostate Specific Antigen (PSA) Screening Study
|
N/A | |
Active, not recruiting |
NCT05732441 -
Therapeutic Study of Prostatitis With Elevated PSA
|
N/A | |
Recruiting |
NCT04393376 -
PSA Glycomics Assay for Early Detection of Prostate Cancer
|
N/A | |
Not yet recruiting |
NCT05306314 -
Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis
|